Introduction
Taxol (Paclitaxel), one of the most clinically eective anti-neoplastic agents currently available, has shown signi®cant promise in the treatment of a number of tumors including metastatic breast and ovarian cancers (reviewed by Rowinsky and Donehower, 1995) . Taxol is an antimicrotubule agent that is believed to mediate its antineoplastic eects by inducing mitotic arrest followed by apoptosis (Rowinsky and Donehower, 1995; Schi et al., 1979; Kumar, 1981; Bhalla et al., 1993) . The mitotic arrest induced by Taxol precedes an increase in microtubule stability and a decrease in microtubule disassembly (Rowinsky and Donehower, 1995; Schi et al., 1979; Kumar, 1981) . However, the molecular mechanisms contributing to Taxol-induced apoptosis remain unclear.
Proteases are important components of the machinery that executes apoptosis. Caspases, in particular, have received widespread attention as important players in the induction of cell death. Caspases belong to a family of cysteine proteases which, upon activation, speci®cally cleave their substrates at aspartic acid residues (reviewed in White, 1996; Takahashi and Earnshaw, 1996; Martin and Green, 1995) . The activation of caspase(s) and the cleavage of their substrates have been observed during apoptosis induced by diverse stimuli (White, 1996; Takahashi and Earnshaw, 1996; Martin and Green, 1995; Tewari et al., 1995; Salvesen and Dixit, 1997) . A number of recent studies have shown that various serine protease inhibitors can also abrogate cell death induced by certain stimuli Wright et al., 1997; Adjei et al., 1996) . This suggests that serine proteases are also likely to play a role in the apoptotic process, but virtually nothing is known about the pathway.
Taxol-induced cell death has been shown to be coupled with the phosphorylation of Bcl-2 in a number of human cancer cell lines (Blagosklonny et al., 1996 (Blagosklonny et al., , 1997 Halder et al., 1996) . Bcl-2 is the prototype of a related group of proteins implicated in regulating apoptosis. Certain members of the family are proapoptotic (i.e. Bad, Bax, Bcl-Xs) while others are anti-apoptotic (i.e., Bcl-2 and Bcl-X L ). The various family members can interact through formation of hetero-and homo-dimeric complexes such that the actual activity seen re¯ects the relative abundance and/ or protein modi®cation of pro-versus anti-apoptotic forms in a given cell under a particular set of conditions (reviewed in Oltvai et al., 1993; Korsmeyer, 1995; Reed, 1997) . Phosphorylation of Bcl-2 is thought to interfere with its ability to heterodimerize with pro-apoptotic proteins such as Bax, thereby blocking its anti-apoptotic function (Halder et al., 1995 (Halder et al., , 1996 .
In addition to enhanced phosphorylation of Bcl-2, Taxol-induced apoptosis is associated with a stimulation of c-Raf-1 phosphorylation and activation of the extracellular signal regulated kinase (ERK) in MCF-7 human breast carcinoma cells (Blagosklonny et al., 1995 (Blagosklonny et al., , 1996 . ERK is a member of the mitogenactivated protein (MAP) kinase family, another group of proteins implicated in the regulation of apoptosis (Johnson et al., 1996) . This family also includes the cJun N-terminal kinases (JNK) and p38 kinase subfamilies (reviewed in Su and Karin, 1996) . c-Raf-1, a serine/threonine kinase, is an important component of the ERK signaling pathway (Kyriakis et al., 1992) . It is responsible for the phosphorylation and activation of MEK, the kinase that lies immediately upstream of ERK (Kyriakis et al., 1992) . Activation of c-Raf-1 and ERK is predominantly associated with proliferative signals, but as seen with Taxol, their activation can also occur in other situations leading to apoptosis. Taxol-induced Bcl-2 phosphorylation is closely associated with c-Raf-1 phosphorylation and ERK2 activation, and indeed, c-Raf-1 appears to be required for Bcl-2 phosphorylation and cell death following Taxol treatment (Blagosklonny et al., 1996) . It remains unclear whether Bcl-2 phosphorylation occurs via the c-Raf-1/ERK-activated signaling cascade. In contrast to ERK, JNK and p38 MAP kinases generally respond weakly to mitogenic stimuli, but are highly activated in response to a wide variety of stimuli that induce apoptosis. JNK activation has been directly correlated with apoptosis in many dierent model systems (Chen et al., 1996; Xia et al., 1995; Derijard et al., 1994; Schwenger et al., 1997) . Whether either JNK or p38 activation plays a role in mediating Taxol-induced cell death has not been addressed.
In this study we investigated the molecular mechanism(s) of Taxol-induced cell death in MCF-7 human breast carcinoma cells. Consistent with previous observations we demonstrate that Taxol-induced apoptosis is tightly associated with stimulation of cRaf-1 and Bcl-2 phosphorylation. We further show that treatment of MCF-7 cells with the serine protease inhibitor TPCK abrogates Taxol-induced cell death and prevents c-Raf-1 and Bcl-2 phosphorylation. ERK activation is not prevented, but in fact is increased in the presence of TPCK, indicating that it can be disassociated from c-Raf-1 and Bcl-2 phosphorylation. Inhibition of ERK activation through use of the MEK activation inhibitor PD98059 does not alter the apoptotic phenotype induced by Taxol. Taken together, our ®ndings support the view that the activations of c-Raf-1 and Bcl-2, but not ERK, are important steps in the pathway(s) leading to Taxolinduced apoptosis in MCF-7 cells, and suggest that a TPCK inhibitable protease(s) plays a role in this process.
Results

Taxol-induced apoptosis is associated with activation of ERK and JNK but not p38 MAP kinases
In agreement with previous ®ndings (Huang et al., 1997b; Saunders et al., 1997) , Taxol-induced apoptosis in MCF-7 cells. Morphological analysis of Taxoltreated cells revealed cardinal features of apoptosis including chromatin condensation and nuclear fragmentation (Figure 1 ). The apoptotic eects of Taxol were both time-and dose-dependent with the maximum eect achieved with a 50 nM concentration for 48 h ( Table 1) .
Activation of MAP kinases is frequently associated with cellular responses to stress (Chen et al., 1996; Xia et al., 1995; Derijard et al., 1994; Schwenger et al., 1997) . Taxol-induced apoptosis of MCF-7 cells has previously been shown to be associated with activation of ERK and JNK (Blagosklonny et al., 1996; Wang et al., 1998) , but the activity of p38 has not been examined. To determine the possible contribution of these MAP kinases during the cellular response to Taxol, we examined ERK, JNK and p38 activities at various times following treatment with 50 nM Taxol. In agreement with previous studies, we observed ERK activation during Taxol treatment (Figure 2a , top panel). JNK activity was also elevated following Taxol treatment as assessed by an immunocomplex kinase assay utilizing c-Jun as a substrate (Figure 2b , top panel). Increased JNK activity was seen within 4.5 h of Taxol addition to MCF-7 cells. Maximum activity was achieved over the time period from 16 ± 24 h and declined thereafter. Consistent with the kinase activity, anti-JNK Western immunoblot analysis performed on the same cell lysates revealed a Taxol-induced shift in the mobility of JNK protein (Figure 2b , lower panel), re¯ecting its hyperphosphorylation. To investigate the eects of Taxol on p38 MAP kinase, we used a phospho-speci®c anti-p38 antibody which recognizes only the activated form of p38. As shown in Figure 2c , no phosphorylated p38 kinase was detected in Taxoltreated MCF-7 cells, although the antibody was able to recognize the activated form of p38 in the lysates of H 2 O 2 -treated HeLa cells on the same membrane. Reprobing of the same blot with an antibody that recognizes p38 MAP kinase independent of its Figure 1 Taxol induces apoptosis of MCF-7 human breast carcinoma cells. Cells were either left untreated (Control) or were treated with 50 nM Taxol for 48 h after which they were processed for apoptosis analysis as described in Materials and methods. Representative photomicrographs depicting nuclear morphology were taken at 4006magni®cations (Figure 2c , lower panel). Thus, Taxol treatment results in the activation of ERK and JNK, but not p38 MAP kinase in these cells.
Lack of involvement of caspases 1 and 3 in Taxol-induced apoptosis of MCF-7 cells
Proteases have been identi®ed as important components of the machinery that executes apoptosis. To gain insight into the possible mechanism(s) of Taxolinduced cell death, we investigated the involvement of various proteases utilizing several strategies. We began by examining the potential role of caspases in the response. Caspases have been shown to be involved in apoptosis induced by various stresses in dierent systems (reviewed in Takahashi and Earnshaw, 1996; Martin and Green, 1995; Martins and Earnshaw, 1997) . To address their possible contribution to Taxol-induced apoptosis, we examined the eects of two caspase inhibitors, Ac-YVAD-CHO (speci®c for caspase 1; ICE) and Ac-DEVD-CHO (speci®c for caspase 3; CPP32/Yama/apopain) (Thornberry et al., 1992; Nicholson et al., 1995; Lazebnik et al., 1994; JaÈ nicke et al., 1998) on survival of Taxol treated cells.
The results shown in Figure 3a indicate that neither inhibitor in¯uenced the apoptotic response to Taxol, suggesting a lack of involvement of caspases 1 and 3 in Taxol-induced apoptosis of MCF-7 cells. To more directly address the role of caspases in the apoptotic response, we examined lysates from Taxol-treated cells for evidence of PARP cleavage products. PARP has been identi®ed as a common substrate for multiple caspases that, upon activation, cleave the 116 kDa protein resulting in the appearance of an 85 kDa fragment (reviewed in Lazebnik et al., 1994; Martins and Earnshaw, 1997; Tewari et al., 1995) . Consistent with the lack of eect of the caspase inhibitors on apoptosis, we found no evidence of PARP cleavage in Taxol-treated MCF-7 cells even with prolonged treatment (Figure 3b ). That the antibody and conditions utilized would detect such cleavage products is evidenced by the fact that an 85 kDa cleavage product was detected in both etoposide-and Taxoltreated human lung cancer A549 cell lysates analysed on the same membrane. Curiously, we did see a reduction in PARP levels with prolonged Taxol treatment, the cause of the decline of this protein is not known. Western analysis of MCF-7 cells for caspases 2 and 3 activation following Taxol treatment also failed to provide evidence that these caspases are involved in the response to Taxol. First, MCF-7 cells were found not to express caspase 3, even though we clearly detected the expression and cleavage of caspase 3 on the same membrane from cell lysates of two other cell lines, H1299 and A549, after UV or etoposide treatment ( Figure 3c ). In addition, we also failed to detect the expression of caspase 1 in these MCF-7 cells (data not shown). Although MCF-7 cells did express caspase 2, Taxol treatment failed to result in its cleavage ( Figure 3d ). As a ®nal approach to address the role of caspases in Taxol-induced apoptosis in these cells, we examined the eect of CrmA overexpression on Taxol-induced apoptosis. CrmA is a serpin from cowpox virus which has been shown to act as a speci®c inhibitor of caspases including caspase 1, caspase 3 and caspase 8 (FLICE) (Tewari et al., 1995; Zhou et al., 1997) . Although pooled clones of stably transfected MCF-7 cells expressing high levels of exogenous CrmA protein, these CrmA-transfected cells did not dier from the mock-transfected cells in their sensitivity to Taxol-induced apoptosis (data not shown). Taken together, the ®ndings obtained above indicate that caspases (at least caspases 1, 2 and 3) are not involved in mediating apoptosis of Taxol-treated MCF-7 cells.
The serine protease inhibitor TPCK prevents Taxol-induced apoptosis
To further dissect the Taxol-induced apoptotic signaling, we next examined the ability of two serine protease inhibitors, TLCK and TPCK, to alter the apoptotic response to Taxol treatment. These inhibitors show dierential speci®cities in that TLCK inhibits serine proteases of the trypsin type, while TPCK inhibits proteases of the chymotrypsin type (Tudela et al., 1986; Pasternack and Eisen 1985; Baker and Eisen, 1977; Wilson et al., 1989) . As shown in Figure 4a , TLCK had no eect on Taxol-induced apoptosis. In contrast, TPCK almost completely abrogated the Taxol-induced apoptotic features (such as nuclear condensation and fragmentation) observed by DAPI Figure 2 Eect of Taxol on the activity of MAP kinases in MCF-7 cells. (a) ERK activation was determined at various times following Taxol treatment by an immunocomplex kinase assay using MBP as substrate (upper panel). Samples of the same cell lysates were also subjected to Western blot analysis using anti-ERK2 speci®c antibodies (lower panel). (b) Taxol-induced changes in JNK activity were determined using a GST-c-Jun fusion protein as substrate (upper panel). JNK1 expression was assessed by Western blot analysis using anti-JNK1 speci®c antibodies (lower panel). (c) p38 activation was examined by Western blot analysis using phosphospeci®c anti-p38 antibodies.
Lysates from H 2 O 2 -treated Hela cells were included as a positive control for the detection of activated/phosphorylated p38 MAP kinase (upper panel). The same blot was stripped and reprobed with an anti-p38 antibody which recognizes both phosphorylated and non-phosphorylated forms of p38 kinase (lower panel)
nuclear staining in these cells (Figure 4a and b) . Importantly, TPCK not only suppressed the morphological changes induced by Taxol (Figure 4b ), but also aected the long-term survival of MCF-7 cells as determined by colony formation assays. As shown in Figure 4c and Table 2 , few cells survived and developed into colonies from plates treated with Taxol alone. In contrast, plates treated with Taxol plus TPCK showed a large number of colonies ( Figure 4c and Table 2 ) indicating that TPCK did enhance long term survival of Taxol-treated cells. These results implicate serine protease(s) of the chymotrypsin type in mediating Taxol-induced apoptosis of MCF-7 cells. These eects are not limited to MCF-7 cells, as testing of two other breast cancer cell lines, T47D and MDA435, revealed that both were signi®cantly protected against Taxol-induced death by co-treatment of TPCK (Table 3) . These results suggest that Taxol may activate a common cell death pathway in breast cancer cells that can be blocked by the serine protease inhibitor TPCK.
Eect of TPCK on MAP kinase activities and c-Raf-1 and Bcl-2 phosphorylation in Taxol-treated cells
In order to gain further insight into the mechanisms associated with Taxol-induced death of MCF-7 cells, we examined the ability of TPCK to alter various responses to Taxol treatment. Given that JNK has been implicated in the induction of cell death by a wide variety of treatments and our observation that JNK was induced in Taxol-treated cells undergoing apoptosis, we examined whether TPCK might alter JNK activation in response to Taxol treatment. As shown in Figure 5 , TPCK did not signi®cantly alter Taxol-induced JNK kinase activity although TPCK did eciently block cell death caused by Taxol treatment. Hence, either JNK activation is not important for the induction of cell death by Taxol, or TPCK acts downstream of JNK to in¯uence survival. In any case, TPCK clearly does not act to inhibit the cellular response to Taxol through modulation of JNK activity. Since Taxol treatment is associated with enhanced phosphorylation of c-Raf-1, Bcl-2 and ERK, we next examined the in¯uence of TPCK treatment on these events (Figure 6 ). Lanes 1 ± 5 of Figure 6 show the time course for phosphorylation of these three proteins following addition of Taxol in the absence of TPCK. Phosphorylation was evidenced by either enhanced band intensity in the case of ERK, or a shift in the electrophoretic mobilities of c-Raf-1 and Bcl-2 proteins. Interestingly, the kinetics of the Raf-1 and Bcl-2 phosphorylations were tightly linked (Figure 6 and 8), while the ERK phosphorylation preceded that of c-Raf-1 and Bcl-2 (Figure 6 ). Importantly, TPCK treatment led to signi®cant enhancement of ERK phosphorylation, but completely inhibited the Taxolinduced shift in the mobilities of c-Raf-1 and Bcl-2. This ®nding indicates that ERK phosphorylation is not coupled to c-Raf-1 and Bcl-2 phosphorylation. We and others have shown that in certain situations ERK activation is associated with enhanced cell survival (Guyton et al., 1996; Xia et al., 1995) . Therefore it was of interest to determine whether the elevation of ERK activity seen in TPCK plus Taxol-treated cells contributed to their increased survival. To do this we used an inhibitor of MEK activation, PD98059, to block ERK activation during Taxol treatment. As shown in Figure 7a , treatment of the cells with PD98059 eectively blocked ERK phosphorylation by Taxol both in the absence and presence of TPCK. However, under no circumstance did it alter the survival of Taxol-treated cells (Figure 7b ). Treatment with PD98059 also had no eect on changes in the electrophoretic mobilities of either c-Raf-1 or Bcl-2 induced by Taxol (Figure 8 ). In comparison, phosphorylation of c-raf-1 induced by Taxol was almost completely blocked by TPCK (Figures 8c and 6 ). Taken together, our ®ndings support a role for phosphorylation of c-Raf-1 and Bcl-2, but not ERK1/2 in the mechanism leading to Taxol-induced apoptosis.
Discussion
In the study reported here we have investigated the mechanism of Taxol-induced apoptosis in MCF-7 human breast carcinoma cells. Our ®nding that TPCK completely prevented Taxol-induced cell death suggests that the pathway leading to apoptosis in response to Taxol involves a chymotrypsin-like serine protease. This appears to be speci®c for chymotrypsin-like proteases as no prevention of cell death was seen with TLCK, which targets trypsin-like serine proteases. Importantly, this protective eect of TPCK was not Figure 5 TPCK does not alter JNK activation by Taxol. MCF-7 cells were either left untreated or were treated with Taxol alone or TPCK plus Taxol. JNK activity was analysed at the indicated times using an immunocomplex kinase assay and GST-c-Jun fusion protein as substrate Figure 6 Eect of TPCK on Taxol-induced ERK, c-Raf-1 and Bcl-2 phosphorylation. MCF-7 cells were either left untreated (controls) or were treated with Taxol alone (50 nM), TPCK (10 mM) alone, or TPCK plus Taxol. Cell lysates were harvested at the indicated times after Taxol addition and subjected to Western analysis. The same blot was sequentially probed with phosphospeci®c anti-ERK, anti-c-Raf-1 and anti-Bcl-2 antibodies as indicated limited to MCF-7 cells as the protease inhibitor also prevented the apoptotic response to Taxol treatment in two other breast cancer cell lines, T47D and MDA435 (Table 3) .
Although the role of serine proteases in cell death remains largely unexplored, a number of studies have shown that serine protease inhibitors can block apoptosis induced by certain stimuli Adjei et al., 1996 , Dong et al., 1997 Chow et al., 1995; Weis et al., 1995; Mansat et al., 1997; Shao et al., 1997) . For example, TPCK has been shown to inhibit both FAS antigen-and p53-induced apoptosis as well as cell death occurring in response to various chemotherapeutic agents (e.g. etoposide, UCN-01, and daunorubicin) in cells of hematopoietic origin Mansat et al., 1997; Shao et al., 1997; Sebestyen et al., 1997; Lotem and Sachs, 1996) . TLCK on the other hand, was found to be eective in inhibiting cell death by camptothecin and glycodeoxycholate in hepatocytes, but TPCK was without eect (Kwo et al., 1995 , Adjei et al., 1996 . Thus, it is likely that the role of speci®c serine proteases is dependent on both the cell type and agent examined. However, in no case has the particular protease involved yet been identi®ed and this remains an important area of investigation for future studies. In addition to acting as serine protease inhibitors both TPCK and TLCK can function as alkylating agents (Cromlish and Roeder, 1989) . The selective inhibition of Taxolinduced apoptosis by TPCK, but not TLCK suggests that the serine protease inhibitory activity rather than the alkylating activity is important for this eect.
In some of the cases noted above, serine proteases may act in conjunction with caspases to induce cell death as caspases are also activated Lotem and Sachs, 1996) . In fact a recent report by Shen et al. (1998) has implicated caspases in the induction of apoptosis by Taxol in MCF-7 cells. They showed evidence for the activation of caspase 3 and cleavage of poly (ADP-ribose) polymerase during Taxol treatment (Shen et al., 1998) . In contrast to this study, we did not observe any caspase-3 expression in our MCF-7 cells (Figure 3c ). Indeed, while this manuscript was in its ®nal stage of preparation, a paper by JaÈ nicke et al. (1998) was published con®rming this ®nding. They demonstrated that the lack of caspase 3 protein in MCF-7 cells is due to a 47 bp deletion found on the exon 3 of caspase 3 gene which resulted in a premature stop codon of caspase 3 mRNA (JaÈ nicke et al., 1998). Consistent with our observation, this group has also failed to detect caspase 1 expression in MCF-7 cells (JaÈ nicke et al., 1998). We also have not seen evidence of PARP cleavage following Taxol treatment in our MCF-7 cell line (Figure 3b ). In addition, neither the treatment of cells with peptide caspase inhibitors Ac-YVAD-CHO and Ac-DEVD-CHO (Figure 3a) nor overexpression of exogeneous of CrmA was found to inhibit Taxolinduced apoptosis in our MCF-7 cells. Based on this evidence, we conclude that neither caspase 1 nor caspase 3 contributes to Taxol-induced cell death in these MCF-7 cells. Additional studies examining the expression of caspase 2 by Western analysis also failed to suggest a role of this caspase in response to Taxolinduced apoptosis. Importantly, these studies do not rule out the possible involvement of caspases in mediating Taxol-induced cell death in other cell types as we have demonstrated that Taxol treatment does result in PARP cleavage in human lung carcinoma A549 cells (Figure 3b) and Ibrado et al. (1996) have shown evidence of PARP cleavage in the human myeloid leukemia cell line HL-60.
We have demonstrated that in MCF-7 cells Taxol treatment leads to the activation of ERK and JNK MAP kinases, but has no eect on p38 MAP kinase. JNK has been implicated in the implementation of programmed cell death in response to a variety of stressful stimuli, but the downstream eectors involved in mediating its apoptotic eects have not been identi®ed. A recent report demonstrated that JNK was capable of phosphorylating Bcl-2 (Maundrell et al., 1997) , suggesting the possibility that JNK could play a role in Taxol-induced Bcl-2 phosphorylation. However, our ®nding that TPCK did not aect the level of JNK activity seen in response to Taxol treatment although it completely prevented Bcl-2 phosphorylation, argue against this possibility. In any case, it is clear that either JNK activity is not important for Taxol-induced death, or TPCK acts downstream of JNK to regulate Bcl-2 and apoptosis.
Previous studies had demonstrated the phosphorylation of ERK, Raf-1 and Bcl-2 in response to Taxol treatment (Blagosklonny et al., 1996; Halder et al., 1996; Wolfson et al., 1997) . ERK is known to be activated via a phosphorylation cascade involving the Ras/Raf/MEK pathway. Phosphorylation of c-Raf-1 on tyrosine/serine residues generally results in its activation allowing for the subsequent activation of MEK, which in turn phosphorylates and activates ERK. ERK is responsible for the phosphorylation of a variety of proteins. The studies by Blagosklonny et al. (1996) demonstrated that depletion of c-Raf-1 was associated with abrogation of Taxol-induced apoptosis as well as Bcl-2 phosphorylation. Our results con®rm the ®nding that Taxol-induced apoptosis is coupled with c-Raf-1 and Bcl-2 phosphorylation. However, our studies do not support a role for ERK in the induction of the death pathway. First, the kinetics of ERK activation and changes in the mobility (phosphorylation) of c-Raf-1 following Taxol treatment are discordant. Second, TPCK treatment did not prevent, but rather enhanced ERK activation in response to Taxol treatment. Finally, inhibition of ERK activation through use of the inhibitor of MEK activation PD98059 neither altered the apoptotic response to Taxol (Figure 7 ) nor the phosphorylation of c-Raf-1 or Bcl-2 (Figure 8 ). These ®ndings demonstrate that although Taxol stimulated phosphorylation of c-Raf-1 and Bcl-2 are tightly coupled, they can be disassociated from ERK activity. ERK activation does not correlate with the apoptosis, while phosphorylation of c-Raf-1 and Bcl-2 does. Taken together our ®ndings support the notion that c-Raf-1 and Bcl-2 phosphorylations are important events in the cellular response to Taxol treatment leading to cell death. It is of note that c-Raf-1 contains multiple potential serine and tyrosine phosphorylation sites (Diaz et al., 1997; Fabian et al., 1993; Morrison and Cutler, 1997; Kasid et al., 1996; Mischak et al., 1996) . Phosphorylation on dierent residues has been shown to dierentially regulate the enzymatic and biologic activity of the protein (Diaz et al., 1997; Fabian et al., 1993; Morrison and Cutler, 1997; Kasid et al., 1996; Mischak et al., 1996) . It is likely that at least some of the residues on c-Raf-1 which undergo phosphorylation in response to Taxol treatment dier from those phosphorylated in response to growth factor stimulation. Thus, the kinase(s) that are responsible for c-Raf-1 phosphorylation in response to Taxol treatment may be unique to this agent. The fact that the serine protease inhibitor TPCK prevents phosphorylation of c-Raf-1 during Taxol treatment suggests that a serine protease(s) lies upstream of, or at the level of this c-Raf-1 kinase.
In summary, we have provided the ®rst evidence for the role of a serine protease(s) in the execution of Taxol-induced cell death. Identi®cation of the speci®c protease(s) involved and their relevant substrate(s) could lead to the development of improved therapeutic agents for cancer treatment.
Materials and methods
Antibodies and reagents
The antibodies used in this study and their sources are as follows: anti-active MAP kinase antibody, selective for phosphorylated/activated forms of ERK1 (p44) and ERK2 (p42) (Promega, Madison, WI, USA); anti-phosphospeci®c p38 MAP kinase (Thr180/Tyr182) antibody, which only reacts with phosphorylated p38, and anti-p38 antibody, which recognizes both phosphorylated and non-phosphorylated forms of p38 (New England Biolabs, Beverly, MA, USA); anti-JNK, anti-c-Raf-1 (Transduction Laboratories, Lexington, KY, USA) and rabbit polyclonal anti-Bcl-2 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA and Transduction Laboratories). The serine protease inhibitors TLCK (N-Tosyl-L-Lysine Chloromethyl Ketone), TPCK (N-Tosyl-L-Phenylalanine Chloromethyl Ketone), and Taxol were from Sigma Chemicals (St Louis, MO, USA).
Cell lines and cell culture
MCF-7 cells were obtained from NCI Frederick Cancer Research Facility. Cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) (GIBCO-Life technologies, Inc, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Intergen, NY, USA).
Analysis for apoptosis
Cells were analysed for features of apoptosis as previously described (Sheikh et al., 1995) . Brie¯y, cells growing logarithmically in six well plates or 60 mm dishes were either left untreated or were treated with various concentrations of Taxol for the indicated periods of time. Cells were washed with PBS prior to ®xation with ice cold methanol for 3 ± 5 min. After rehydration for 2 min in PBS, cells were incubated with DAPI (4,6-diamidino-2 phenyl-indole; Sigma Chemicals, St Louis, MO, USA) solution for 30 min in the dark, then were washed with PBS. Cells were analysed using a Zeiss or Olympus¯uorescent microscope. Cells with fragmented nuclei were scored positive for apoptosis. Apoptotic nuclei were counted in several randomly selected ®elds and minimum of 500 ± 1000 nuclei were examined for each case. The results are expressed as the number of apoptotic nuclei over the total number of nuclei counted.
Colony formation assay
Cells seeded at a low density (*5610 4 ) in 100 mm plates were either left untreated or were pretreated with TPCK overnight. On the following day, fresh medium containing Taxol (50 nM) with or without fresh TPCK was added to respective plates for 48 h; cells were washed three times with PBS and TPCK treatment in the absence of Taxol was continued in the respective plates for an additional 24 h. Cells were washed with PBS, and fresh medium without either Taxol or TPCK was added to all plates. After 16 days incubation, cell colonies stained with crystal violet were counted.
Western blot analysis
Protein lysates were extracted from control and Taxol-treated cells and electrophoresed on 10 ± 15% SDS-polyacrylamide gels. The size-separated proteins were transferred to nitrocellulose membranes, which were blocked in 2 ± 5% milk containing 0.01% Tween 20 in PBS. The membranes were then probed with the primary antibodies of interest. All proteins were detected using the enhanced chemiluminescence (ECL) system (Amersham Life Science, Arlington Heights, IL, USA).
Protein kinase assays
The JNK and ERK kinase assays were performed as described previously (Huang et al., 1997a) . Brie¯y, cells treated with or without Taxol were lysed in buer containing 20 mM HEPES, pH 7.4; 2 mM EGTA; 50 mM b-glycerophosphate; 1 mM DTT; 1 mM Na 3 VO 4 ; 5 mM NaF; 1% Triton X-100; 10% glycerol; 10 mM leupeptin; 10 mM aprotinin; 0.1 mg/ ml okadaic acid and 400 mM PMSF. Endogenous JNK1 and ERK2 were immunoprecipitated from cell lysates with antip46 JNK and anti-p42 ERK antibodies, respectively (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Immunoprecipitates were extensively washed and assayed for JNK or ERK kinase activity using GST-c-Jun (provided by J Woodgett) and myelin basic protein (MBP; Sigma Chemical Co.) respectively as substrates. Kinase assays were performed in [g-32 P]ATP (10 mCi/ml) supplemented buer at 308C for 20 min. Radiolabeled GST-c-Jun and MBP products were electrophoresed on 12% and 15% polyacrylamide gels and exposed to X-ray ®lms or PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA) for analysis.
Abbreviations ERK, extracellular signal regulated kinase; JNK, c-Jun Nterminal protein kinase; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone; TLCK, N-p-tosyl-L-lysine chloromethyl ketone; DAPI, 4,6,-diamidino-2 phenyl-indole.
